Journal article
Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease
Annals of neurology
05/10/2026
DOI: 10.1002/ana.78239
PMID: 42108682
Abstract
The Parkinson's Progression Markers Initiative (PPMI) has remained at the vanguard of Parkinson's disease (PD) research through evolving recruitment strategies that mirror advances in PD biology. PPMI was initially focused on untreated, early‐stage PD. Over time, it has expanded to include genetic cohorts, prodromal participants identified via olfactory testing and risk factor questionnaires targeting people with rapid eye movement (REM) sleep behavior disorder (RBD). Most recently, PPMI has focused on the biology underlying PD and sought to recruit individuals defined by neuronal alpha‐synuclein disease (NSD) biomarkers. This evolution from clinical to biological enrollment demonstrates the feasibility of biomarker‐driven cohort design and establishes a scalable model for early detection and prevention research in neurodegenerative disease. ANN NEUROL 2026
Details
- Title: Subtitle
- Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease
- Creators
- Andrew Siderowf - University of PennsylvaniaLaura E.A. Heathers - Indiana University – Purdue University IndianapolisKimberly Fabrizio - Institute for Neurodegenerative DisordersMaggie McGuire Kuhl - Michael J. Fox FoundationCatherine M. Kopil - Michael J. Fox FoundationEmily Flagg - Institute for Neurodegenerative DisordersBridget A. McMahon - Institute for Neurodegenerative DisordersChristopher S. Coffey - University of IowaAudra Bright - Indiana University – Purdue University IndianapolisMichelle Totten - Indiana University – Purdue University IndianapolisLynell P. Lemon - Institute for Neurodegenerative DisordersErinn Bryan - Institute for Neurodegenerative DisordersNeha Prakash - Institute for Neurodegenerative DisordersNicola Pavese - Newcastle UniversityBastiaan R. Bloem - Radboud University NijmegenRoy N. Alcalay - Columbia University Irving Medical CenterAnat Mirelman - Tel Aviv UniversityLeonidas Stefanis - National and Kapodistrian University of AthensNjideka Okubadejo - University of LagosEduardo Tolosa - Consorci Institut D'Investigacions Biomediques August Pi I SunyerCaroline M. Tanner - University of California, San FranciscoTanya Simuni - Northwestern UniversitySohini Chowdhury - Michael J. Fox FoundationThomas F. Tropea - Institute for Neurodegenerative DisordersKenneth Marek - Institute for Neurodegenerative DisordersTatiana Foroud - Indiana University – Purdue University Indianapolisthe Parkinson's Progression Markers Initiative
- Resource Type
- Journal article
- Publication Details
- Annals of neurology
- DOI
- 10.1002/ana.78239
- PMID
- 42108682
- NLM abbreviation
- Ann Neurol
- ISSN
- 0364-5134
- eISSN
- 1531-8249
- Publisher
- Wiley
- Grant note
- MJFF for Parkinson's Research AbbVie BIAL Critical Path Institute Edmond J. Safra Foundation Eli Lilly, Gain Therapeutics GE HealthCare Voyager Therapeutics Weston Family Foundation
PPMI-a public-private partnership-is funded by MJFF for Parkinson's Research and funding partners, including AbbVie, Alamar Biosciences, Aligning Science Across Parkinson's, Arrowhead Pharma, AskBio, BIAL, BioArctic, Biohaven, BlueRock Therapeutics, Bristol-MyersSquibb, Calico Labs, Capsida Biotherapeutics, Critical Path Institute, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Insitro, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Neumora, Neuron23, Novartis, Regeneron, Roche, Sanofi, Tenvie, UCB, VanquaBio, Voyager Therapeutics, and the Weston Family Foundation.
- Language
- English
- Electronic publication date
- 05/10/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985163697902771
Metrics
1 Record Views